Reading PRVA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PRVA free→Reading PRVA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PRVA free→NASDAQHealth CareHealth Information ServicesSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. However, risk is moderate, and the sector backdrop is a headwind, with PRVA trading below typical levels compared to sector peers. Peer multiples imply a price about 15% below where it trades (it looks expensive on this basis); the read is fair, quality intact. This assessment hinges on guidance changes and sector trends, particularly the performance of leading companies in the Healthcare sector. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $23.43. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $23 the market pays 29× p/e — above the 19× p/e peer median but in line with its own 58× history. That premium reflects a durable franchise our peer-anchored $20 fair value understates; treat the 'expensive vs peers' read with medium confidence. Analysts: $24–$36. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 15% near-term growth, below our forecast of about 25%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 6.34x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.25 → $0.25 (-0.6% / 30d). 2 raised, 7 cut, 10 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 90% of analysts rate Buy.
1 PT revisions / 30d. Avg target 5.8% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$146.
How much price usually moves either way.
On a bad day, this stock has moved -$302.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,417.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Company momentum rose by 19.7 points (from -52.5 to -32.8).
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If it goes over 1.6 million, it shows strong growth in patient engagement. It also shows growth in the provider network.
Confirms:Q2 Attributed Lives are above 1,600,000.
Disproves:Attributed Lives are less than 1,600,000.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PRVA yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
of this Current Report on Form 8-K, including Exhibit 99.1, are “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference i…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$24.00 – $36.00 (median $29.00) · 4 analysts · as of 2026-05-26
Looks more expensive than peers.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Services.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
PRVA Privia Health Group, Inc. | Typical Show detailsSector percentile: 35 of 100 | full | moderate |
CVS CVS Health | Typical Show detailsSector percentile: 60 of 100 | fair | moderate |
CI Cigna | Above typical Show detailsSector percentile: 88 of 100 | inexpensive | moderate |
DGX Quest Diagnostics | Typical Show detailsSector percentile: 68 of 100 | full | moderate |
LH Labcorp | Above typical Show detailsSector percentile: 75 of 100 | fair | moderate |
Not enough signal yet.
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on increasing revenue through same-store growth and new provider additions.
Enhance operating income through cost management and efficiency improvements.
Focus on improving cash flow from operations despite current negative cash flow.
Why it matters: Good cash flow is important for how the company uses its money. It shows stability.
Confirms:Cash from operations reports a positive figure in Q2.
Disproves:Cash from operations remains negative in Q2.
Why it matters: Meeting this growth target shows the company is on track with its revenue expansion goal. It is key to management's focus on growth.
Confirms:Q2 revenue growth is reported at 10% or higher year over year.
Disproves:Q2 revenue growth falls below 5% year over year.
Why it matters: A drop in operating income may mean higher costs or problems in operations.
Confirms:Operating income is below $7.4M.
Disproves:Operating income is at or above $7.4M.
Why it matters: A drop in sector revenue growth could signal broader challenges. It affects how investors view Privia's performance.
Confirms:Sector revenue growth falls below its median rate.
Disproves:Sector revenue growth remains stable or increases.
Why it matters: Better operating income helps the company manage costs. It shows improved financial health.
Confirms:Operating income increases from $7.4M in Q1 to $10M or more in Q2.
Disproves:Operating income declines further from $7.4M in Q1.
Why it matters: A better margin shows improved efficiency and cash flow.
Confirms:Adjusted EBITDA margin is up from 36.3% compared to last year.
Disproves:Adjusted EBITDA margin declines or stays flat year over year.
Why it matters: Slower growth may mean problems with making money and running operations.
Confirms:Q2 Practice Collections growth reported below 14.6% year over year.
Disproves:Practice Collections growth reported at or above 14.6%.